Gentian Newsletter Q3-2020 #DiagnosticEfficiency

14. Oct 2020 | 6 min read

Gentian Newsletter Q3-2020 #DiagnosticEfficiency

We are looking forward to sharing news and exciting things that happened in the last few months. We have for example, two webinars we believe you will find interesting: Calprotectin in Sepsis and Clinical value of cystatin C.

COVID-19 is still affecting our lives. Gentian is in the proof of concept phase for a turbidimetric SARS-CoV-2 antibody test, with planned launch 2021. As you will see below, calprotectin has shown to be a valuable marker to predict severity in patients with SARS-CoV-2 infection.

If you need more information or have any questions related to products, distribution or sales you are always welcome to contact us at marketing@gentian.com.

 

The role of Calprotectin in COVID-19 – results from clinical studies

the role of calprotectin in COVID 19 and SARS-CoV-2

Several recent studies have reported increased levels of calprotectin in patients with severe SARS-CoV-2 infection as well as identifying the ability of calprotectin to differentiate between mild and severe forms of the disease and its capability to predict the need for mechanical ventilation and mortality. Read more here.

 

Calprotectin in Sepsis

In relation to World Sepsis Day and Sepsis Awareness Month we have decided to make a short webinar with an overview of research and studies related to calprotectin’s role in diagnosing and monitoring sepsis:

World Sepsis Day calprotectin webinar rec 7664v01

 


Development of a unique high-throughput SARS-CoV-2 antibody assay

Covid 19 - SARS-CoV-2 antibody test


Particle-Enhanced Turbidimetric Immunoassay (PETIA) technology creates an opportunity to significantly increase capacity for SARS-CoV-2 antibody testing, and importantly, at the same time make SARS-CoV-2 serology tests more efficient and easily available.

The project is now in the proof-of-concept phase, with a strong focus on technical feasibility and market assessment to further specify the project and assay development. Read more here.

For more information: marketing@gentian.com

 

New release: BÜHLMANN fPELA® turbo

20200608_fPELA-Announcement-picture_News-Post_V02_small-1Turbidimetric assay to help monitor Pancreatic Exocrine Insufficiency.

Gentian and BÜHLMANN are the reagent provider and manufac-turer for the BÜHLMANN fPELA® turbo immunoassay. The immunoassay is sold through Gentian’s partner BÜHLMANN.

 


GCAL® Calprotectin Assay now available for plasma and serum samples

Due to customer demand and clinical practice, we have added a serum sample option to the GCAL® calprotectin immunoassay product range. This will give clinicians a greater choice of sample matrix for diagnosing severe infections in critically ill patients.

Lithium heparin plasma will continue to be available. Order codes will remain the same.

Information and ordering: marketing@gentian.com 

Calprotectin An early biomarker for the diagnosis of bacterial infections and sepsis

 

Webinar: The clinical value of cystatin C, by Dr. E. Sundrehagen, CSO

In this webinar Dr. Erling Sundrehagen, the co-founder of Gentian and the company’s CSO, will elaborate on the clinical value of cystatin C and how cystatin C is a superior glomerular filtration rate (GFR) marker for the diagnosis and therapeutic control of renal function:

Erling final 20.09.02

 

 

Clinical use of canine CRP - interview with Dr. Anna Hillström

We have discussed the clinical use of the measurement of canine C-reactive protein (CRP) with Dr. Anna Hillström, clinical pathologist at the University Animal Hospital (UDS) of the Swedish University of Agricultural Sciences (SLU).

In this interview, Dr. Hillström discusses CRP as a first-line test in diagnosis and clinical decision levels, as well as practical examples from the clinic.

 

Canine crp immunoassay - diagnostics


Cystatin C - a helpful tool for accurate drug dosing

drugdosing-test2

 

A lot of drugs, especially antibiotics and cytotoxic drugs, such as vancomycin, carboplatin, and digoxin, are metabolised and excreted through the kidneys. When prescribing medicine that has a narrow therapeutic window, it becomes exceedingly important to have an accurate understanding of the patients’ Glomerular Filtration Rate (GFR). Cystatin C correlates closely with the mGFR, and cystatin C testing can therefore improve patient treatment. Correct dosing will also create cost savings, due to more effective treatment and shorter recovery time.

Want to learn how a hospital network in the US managed to save cost and shorten length of stay by introducing cystatin C testing as part of vancomycin dosing and treatment? Contact us through marketing@gentian.com and our Product Manager for Cystatin C will contact you.

You may also read


New study results confirm the value of calprotectin in management of COVID-19 patients

Nov 20, 2020

New study results confirm the value of calprotectin in management of COVID-19 patients

New study results from a study conducted in collaboration with Charité – Universitätsmedizin Berlin and Labor..

Gentian at AACC 2020

Nov 12, 2020

Gentian at AACC 2020

Meet us at #2020AACC Virtual Exhibit Hall  Gentian looks forward to meeting you at the AACC 2020, even it..

Gentian Newsletter Q3-2020 #DiagnosticEfficiency

Oct 14, 2020

Gentian Newsletter Q3-2020 #DiagnosticEfficiency

We are looking forward to sharing news and exciting things that happened in the last few months. We have for..